Clinical Trial Technology Editorial

  1. Will Virtual Trials Mean The End Of CROs?

    Virtual trials are growing in acceptance. The patient-centric aspect of these trials makes them easier to recruit and retain patients and accelerate timelines, while also providing patient data to researchers in real time. But will virtual trials also mean the end of CROs?

  2. Driving Innovation: Blockchain Adoption For Clinical Trials Optimization

    Pharmaceutical companies and research institutions are feeling the pressure to reduce the time, financial, and other resource costs associated with conducting clinical trials. With the influx of emerging applications for technologies such as machine learning, robotics and automation, and blockchain and other distributed ledger technologies (DLTs), many see a new path to more efficient and effective processes that can address the challenges faced today.

  3. Less Cumbersome Trials Will Reduce Clinical Costs & Timelines

    Antony Loebel, president and CEO for Sunovion Pharmaceuticals, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Loebel discusses CNS innovation, balancing the needs of clinical stakeholders, and the biggest changes we can expect over the next 10 years.

  4. BERG Invests In Biology And AI To Drive New Cures

    A 2017 report published by Deloitte concluded that much of the current stagnation in drug discovery is due to the industry’s limited understanding of the fundamental molecular mechanisms of disease. Dr. Niven Narain, co-founder, president, and CEO of BERG believes getting a handle on those mechanisms is vital to producing more effective therapies in a shorter amount of time.

  5. Can Pharma Move Us From Sick Care To Healthy Care?

    Ian M. Marks, VP R&D Innovation, GSK Consumer Healthcare, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Marks discusses AI, machine learning, virtual trials, and how innovation will help pharma move from “making us better” to “keeping us well.”

  6. Innovation Will Overcome Time & Cost Challenges Of Clinical Trials

    Rob Scott, M.D., Chief Medical Officer and VP of Development for AbbVie, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Scott discusses clinical innovation, patient voice, and the clinical challenges the pharmaceutical industry still needs to overcome.

  7. AI And Machine Learning Help Unravel The Biology Of Alzheimer’s

    Alkahest is a clinical stage company with multiple products in Phase 2 trials. The company is hoping to develop a treatment for patients with Alzheimer’s by looking at the plasma proteome and, specifically, how it changes with age. This has created a big data challenge for the company.

  8. DPHARM 2019: Emerging Technologies Set To Disrupt Clinical Trials

    DPHARM: Disruptive Innovations is an annual conference that focuses on the innovators shaping the future of trials. Its goal is to bring together disruptive thinkers and change makers to discuss and share ideas on how to transform drug development. In this Q&A, Tammy Guld, global team lead in Janssen Clinical Innovation and co-chair at this year’s conference, shares her key take-aways from the 2019 event.

  9. What Will Clinical Trials Look Like In 10 Years? Experts Forecast 3 Key Trends

    Clinical research has benefited from several advancements in recent decades. Expanding access to information has empowered patients to have greater autonomy in their care and a voice during the development process. Personalized medicine has given rise to promising new therapies treating smaller, more targeted populations. And the number of clinical trials leveraging virtual health tools and mobile technology is increasing. But seismic challenges still remain.

  10. RWE In Clinical Research: Challenges, Opportunities, And 2 Case Studies To Move Us Forward

    This is the second article in a two-part series addressing real-world evidence (RWE) for life sciences leaders who may be struggling to make sense of the rules. In this part, we will explore the challenges and opportunities RWE presents for life sciences companies, review two recent examples, and discuss how this newer way of thinking will transform the way we design and conduct clinical research or evaluate value-based decisions for the better.